This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD). The data are from Part B of COMP006, the company’s larger (n=581) Phase 3 trial that initially assessed two doses of either 1 mg, 10 mg, or 25 mg of psilocybin 3 weeks apart. The primary endpoint was met, Compass shared in February, when it reported a…
